Valente Manuela sold $79K of SOPH

Valente Manuela (Chief People Officer) sold 10,000 shares of SOPHiA GENETICS SA (SOPH) at $7.94 on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Valente Manuela
Published Aug 21, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
high confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market impact.

02

Market read

Small insider sale; unlikely to affect trading decisions.

03

What to watch

Potential upcoming dilution or financing activities that may affect future insider holdings.

Relevance 2/10Novelty 4/10Timing: Filed on 2026‑08‑21 (same‑day filing)

Background

Form 4 filings disclose insider transactions; a 10b5‑1 sale by a senior officer is a standard compliance filing.

Company-level read

Ticker impact

$SOPHNeutralHigh confidence
Context

Chief People Officer Valente Manuela sold 10,000 shares for $79,439 via a 10b5‑1 plan, reducing her stake to 210,450 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to market cap and follows a pre‑arranged plan, indicating no new information about the company's fundamentals.

Market effects

No broader sector impact; insider sales are routine in biotech.

Limited to European markets where SOPHiA is headquartered.

Minimal global relevance.

Counterpoint

If insiders are consistently selling, it could signal concerns not reflected in the price.

Key entities

  • SOPHiA GENETICS SA

    Swiss biotech firm listed on NASDAQ under SOPH.

  • Valente Manuela

    Chief People Officer of SOPHiA GENETICS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September